Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 142 of the 142 references it cites were found in a registry or an index.

Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis

Open access

Abstract

BACKGROUND: Targeting CTLA-4 is a recent strategic approach in cancer control: blocking CTLA-4 enhances an antitumor immunity by promoting T-cell activation and cytotoxic T-lymphocyte proliferation. This induction of a tolerance break against the tumor may be responsible for immune-related adverse events (irAEs). Our objective was to assess the incidence and nature of irAEs in oncologic patients receiving anti-CTLA-4 antibodies (ipilimumab and tremelimumab). METHODS: A systematic search of literature up to February 2014 was performed in MEDLINE, EMBASE, and Cochrane databases to identify relevant articles. Paired reviewers independently selected articles for inclusion and extracted data. Pooled incidence was calculated using R(©), package meta. RESULTS: Overall, 81 articles were included in the study, with a total of 1265 patients from 22 clinical trials included in the meta-analysis. Described irAEs consisted of skin lesions (rash, pruritus, and vitiligo), colitis, and less frequently hepatitis, hypophysitis, thyroiditis, and some rare events such as sarcoidosis, uveitis, Guillain-Barré syndrome, immune-mediated cytopenia and polymyalgia rheumatic/Horton. The overall incidence of all-grade irAEs was 72 % (95 % CI, 65-79 %). The overall incidence of high-grade irAEs was 24 % (95 % CI, 18-30 %). The risk of developing irAEs was dependent of dosage, with incidence of all-grade irAEs being evaluated to 61 % (95 % CI, 56-66 %) for ipilimumab 3 mg/kg and 79 % (95 % CI, 69-89 %) for ipilimumab 10 mg/kg. Death due to irAEs occurred in 0.86 % of patients. The median time of onset of irAEs was about 10 weeks (IQR, 6-12) after the onset of treatment, corresponding with the first three cycles but varied according to the organ system involved. Such immune activation could also be indicative for tumor-specific T-cell activation and irAE occurrence was associated with clinical response to CTLA-4 blocking in 60 % of patients. CONCLUSION: The price of potential long-term survival to metastatic tumors is an atypical immune toxicity, reflecting the mechanism of action of anti-CTLA-4 antibodies. A better knowledge of these irAEs and its management in a multidisciplinary approach will help to reduce morbidity and therapy interruptions.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12916-015-0455-8

Cites

142 of 142 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Mechanism of action: CTLA-4 and anti-CTLA-4 antibodies. Two signals are required to initiate an immune response. For the first signal (signal 1), tumor associated antigen (Ag), is presented by major histocompatibility complex (MHC) on antigen presenting cell (APC) and recognized by the toll-like receptor (TCR) of T-cell. Signal 2 occurs in response to binding of CD80 or CD86 (B7) on APC cell with CD28 receptor on T-cell (a). CTLA-4 is a homolog of CD28 and limits proliferative response of activated T-cell competing with CD28 for ligand B7. This inhibition occurs in response to binding of CD80 or CD86 on APC with CTLA-4 receptor on T-cell and interrupts signal 2 (b). Anti-CTLA-4 antibodies blocks CTLA-4 and enhances T-cell activation and proliferation (c)
Fig. 1 Mechanism of action: CTLA-4 and anti-CTLA-4 antibodies. Two signals are required to initiate an immune response. For the first signal (signal 1), tumor associated antigen (Ag), is presented by major histocompatibility complex (MHC) on antigen presenting cell (APC) and recognized by the toll-like receptor (TCR) of T-cell. Signal 2 occurs in response to binding of CD80 or CD86 (B7) on APC cell with CD28 receptor on T-cell (a). CTLA-4 is a homolog of CD28 and limits proliferative response of activated T-cell competing with CD28 for ligand B7. This inhibition occurs in response to binding of CD80 or CD86 on APC with CTLA-4 receptor on T-cell and interrupts signal 2 (b). Anti-CTLA-4 antibodies blocks CTLA-4 and enhances T-cell activation and proliferation (c)CC BY · PubMed Central
Fig. 2 Flow diagram for identification and selection of studies included in the systematic review and meta-analysis
Fig. 2 Flow diagram for identification and selection of studies included in the systematic review and meta-analysisCC BY · PubMed Central
Fig. 3 Incidence of global immune-related adverse events (irAEs) with anti-CTLA-4, all-grade (a) and severe grade (b). For ipilimumab treatment, different dosages were used: 3 mg/kg, 10 mg/kg, and 15 mg/kg. Only one study [31] reported global irAEs with tremelimumab treatment, at 15 mg/kg dosage. IrAEs associated with anti-CTAL-4 antibodies (c)
Fig. 3 Incidence of global immune-related adverse events (irAEs) with anti-CTLA-4, all-grade (a) and severe grade (b). For ipilimumab treatment, different dosages were used: 3 mg/kg, 10 mg/kg, and 15 mg/kg. Only one study [31] reported global irAEs with tremelimumab treatment, at 15 mg/kg dosage. IrAEs associated with anti-CTAL-4 antibodies (c)CC BY · PubMed Central
Fig. 4 Risk ratio of developing an irAE with ipilimumab at 10 mg/kg compared with 3 mg/kg for global irAEs all grade (a) and high grade (b)
Fig. 4 Risk ratio of developing an irAE with ipilimumab at 10 mg/kg compared with 3 mg/kg for global irAEs all grade (a) and high grade (b)CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 142 references

Research works printed but not linked: 1

  1. Salenave J, Chanson P, Young J. Hypophysite lymphocytaire. Endocrinologie-Nutrition, 10-023-D-10. Paris: Elsevier Masson SAS; 2007.

Cited by

See all 750

Metadata

Authors
Bertrand, A., Kostine, M., Barnetche, T., Truchetet, M.-E., & Schaeverbeke, T.
Affiliations
  • Centre Hospitalier Universitaire de Bordeaux (FR)
  • Centre National de la Recherche Scientifique (FR)
  • Université de Bordeaux (FR)
Corresponding author
Bertrand, Anne
Venue
BMC Medicine
Published
2015-09-04
Volume
13
Issue
1
Pages
211-211
ISSN
1741-7015 (ISSN-L)
OpenAlex
W1914776013
Cited by
704
References
142
Citations by year
2026: 25 · 2025: 33 · 2024: 48 · 2023: 65 · 2022: 65 · 2021: 72 · 2020: 95 · 2019: 99 · 2018: 75 · 2017: 76 · 2016: 48 · 2015: 1
FWCI
7.15
Type
journal article
Language
en
Open access
Locations
  • BMC Medicine (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
Keywords
CTLA-4 blockade, ipilimumab, tremelimumab, immune checkpoint inhibitors, immunotoxicity, rash, colitis, hepatitis, hypophysitis, thyroiditis, dose-dependent toxicity, adverse event incidence, time to onset of adverse events, treatment response, cancer immunotherapy, metastatic cancer, vitiligo
MeSH terms
Ipilimumab, Antibodies, Monoclonal, Antineoplastic Agents, Humans, Immunologic Factors, Immunotherapy, Neoplasms, CTLA-4 Antigen, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis. https://app.cochat.ai/papers/10.1186/s12916-015-0455-8
The paper
Bertrand, A., Kostine, M., Barnetche, T., Truchetet, M.-E., & Schaeverbeke, T. (2015). Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis. BMC Medicine. https://doi.org/10.1186/s12916-015-0455-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.